Intellia Therapeutics

Intellia Therapeutics

Intellia Therapeutics

Treating genetic disease at the cutting edge: Intellia Therapeutics is a CRISPR/Cas9 focused biotechnology company.
Founded
2014
Raised
$193M
Follow us
Alexa global traffic share
Twitter followers
Latest funding Show all
$108,000,000
IPO - 2016
$70,000,000
Venture capital (Series B) - 2015
Team Size
10+
Employees
Xconomy

CRISPR Drug Maker Intellia Therapeutics Sells $108M In IPO Shares

Science Health
Xconomy

With CRISPR in Humans On The Horizon, Will the Public Back Intellia?

Science
Xconomy

CRISPR Developer Intellia Deals With Regeneron, Jumps Into IPO Queue

Science